Lung Cancer
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN, Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T), Danelle Johnston, MSN, RN, HON-ONN, OCN
December 2019 Vol 10, No 12 | December 2, 2019
The CAPE program provides pertinent patient education, best practice information, and resources to patients at their most relevant time in their journey.
December 2019 Vol 10, No 12 | December 2, 2019
The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.
Web Exclusives | November 25, 2019
- Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN, Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T), Danelle Johnston, MSN, RN, HON-ONN, OCN
August 2019 Vol 10, No 8 | August 5, 2019
Lung cancer is the second most common cancer in the United States and has been shown to cause considerable symptom burden in both patients and their caregivers.
2019 Fourth Annual Oncology Guide to New FDA Approvals | June 19, 2019
Lung and bronchus cancer, the second most common form of cancer, accounts for 13.5% of all new cancer cases in the United States. In 2018 alone, lung cancer was newly diagnosed in 234,030 individuals and accounted for 154,050 deaths. In fact, lung cancer is the leading cause of cancer-related mortality in men and women, and is responsible for more than 25% of all cancer deaths. The 5-year survival rate for patients whose lung cancer has spread regionally (to regional lymph nodes) is 29.7%, but that survival rate is only 4.7% for patients with distant metastases.
2019 Fourth Annual Oncology Guide to New FDA Approvals | June 19, 2019
Lung and bronchus cancer is the second most common form of cancer in the United States. In 2018, lung cancer was newly diagnosed in 234,030 individuals, representing 13.5% of all new cancer cases. Lung cancer remains the leading cause of cancer mortality in men and women, accounting for more than 25% of all cancer deaths, which translated to 154,050 deaths in 2018. The relative 5-year survival rate for metastatic lung cancer is only 4.7%.
Web Exclusives | March 22, 2019
For the second time this month, the FDA has given an approval to Genentech’s PD-L1 inhibitor, Tecentriq.
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.